Saluda Medical (ASX:SLD) wins CAP24 FDA nod, unlocking 30% of US SCS market

Neurosurgeons and orthopedic surgeons were locked out of the Evoke story. CAP24 changes the addressable math.

Saluda Medical (ASX:SLD) has secured US FDA approval for its CAP24 surgical paddle lead, and the read for investors is not really about the device itself. It is about which doctors Saluda can now sell to. Until today, the company’s Evoke System was effectively a percutaneous lead product, which closed the door on the surgeon community that prefers to implant via open surgery.

That door has now opened. Neurosurgeons and orthopedic surgeons account for around 30% of all spinal cord stimulation implants in the US, and Saluda’s commercial team was structurally unable to win that business without a paddle lead. CAP24 fixes that, and it does so with a product purpose-built for closed-loop therapy rather than a retrofit of an open-loop design.

Management has flagged a phased US launch in the second half of calendar 2026 with broader rollout later in the year. The revenue contribution will be gradual as surgeon training and field inventory scale up. We think the more important number to track is not near-term sales but the productivity uplift inside the existing US sales force, who can now walk into accounts and cover the full procedural mix instead of being shut out of 30% of cases.

Why CAP24 is more than just another lead in the portfolio

Traditional paddle leads were designed for open-loop stimulation, meaning the device delivers a set dose and hopes for the best. Saluda’s pitch with the Evoke System has always been the opposite, using ECAP sensing (which is essentially measuring the spinal cord’s own electrical response) to adjust therapy in real time to each patient.

The problem was that the existing percutaneous leads only carried this closed-loop benefit to one part of the market. A surgeon who wanted to implant a paddle had to either use a competitor’s open-loop product or skip Saluda entirely. CAP24 is the first paddle lead engineered from the ground up for closed-loop neuromodulation, with a 24-electrode three-column configuration designed specifically for ECAP sensing.

The clinical backbone is the EVOKE randomised trial, which has now reported 36-month durable outcomes in favour of closed-loop over open-loop therapy. That data set is what gives the commercial team a real argument when they walk into a neurosurgery practice.

The addressable market math just shifted

The 30% figure is the headline number, but the second-order effect matters more. Saluda’s existing accounts are already staffed by sales reps who know the Evoke pitch. Adding a paddle lead means the same rep can now cover both pain physicians and surgeons inside the same hospital system, lifting revenue per account without lifting headcount.

This is a margin story as much as a revenue story. SCS is a competitive market dominated by Medtronic, Abbott and Boston Scientific, all of whom carry both percutaneous and paddle options. Saluda has been competing with one hand tied behind its back, and the FDA approval levels the playing field for the first time.

The skeptical read is that converting surgeons takes time. Surgeon training, hospital value analysis committees, and capital equipment cycles do not move on quarterly timelines. We would not expect material paddle revenue until the second half of calendar 2027.

What the surgeon endorsement actually tells us

The Erika Petersen quote in the release is worth reading carefully. She specifically calls out the anatomical design and the integration with EVA Sensing Technology, which suggests Saluda has built something surgeons can actually place reliably rather than a marketing exercise.

Stability and accurate placement are the things that determine whether a paddle lead procedure goes smoothly. Surgeon preference in SCS is sticky, so a credible third-party endorsement at launch helps Saluda’s reps open doors that would otherwise stay closed.

The Investors Takeaway for Saluda Medical

The FDA approval is the easy part. The harder part is converting surgeons who have spent years implanting competitor paddle leads into Saluda accounts, and doing it while the closed-loop clinical narrative is still being communicated to the surgical community.

We think the metrics to watch over the next twelve months are not the absolute paddle revenue number but the count of new surgeon accounts opened, the average revenue per existing account, and any commentary on training throughput. Those will tell investors whether the 30% market expansion is translating into actual procedures or sitting in the pipeline. For readers wanting broader coverage of ASX-listed medical device names, more material is available at stocksdownunder.